Platelet Transfusion-Insights from Current Practice to Future Development

被引:16
作者
Capraru, Annina [1 ,2 ]
Jalowiec, Katarzyna Aleksandra [1 ,2 ]
Medri, Cesare [1 ,2 ]
Daskalakis, Michael [1 ,2 ,3 ]
Zeerleder, Sacha Sergio [1 ,2 ,3 ,4 ,5 ]
Mansouri Taleghani, Behrouz [1 ,2 ]
机构
[1] Univ Bern, Bern Univ Hosp, Inselspital, Dept Hematol, CH-3010 Bern, Switzerland
[2] Univ Bern, Bern Univ Hosp, Inselspital, Cent Hematol Lab, CH-3010 Bern, Switzerland
[3] Univ Bern, Dept Biomed Res, CH-3010 Bern, Switzerland
[4] Sanquin Res, Dept Immunopathol, NL-1006 AD Amsterdam, Netherlands
[5] Landsteiner Lab, NL-1006 AD Amsterdam, Netherlands
关键词
platelet transfusion guidelines; platelet transfusion alternatives; platelet additive solutions; platelet pathogen inactivation; reduction; cold stored platelet concentrates; ACUTE LUNG INJURY; DIPHOSPHATE-ENCAPSULATED LIPOSOMES; PATHOGEN INACTIVATION TECHNOLOGY; TRANSMITTED BACTERIAL-INFECTION; FREEZING HUMAN PLATELETS; ANTI-D ALLOIMMUNIZATION; HEPATITIS-E VIRUS; IN-VITRO; CRYOPRESERVED PLATELETS; LYOPHILIZED PLATELETS;
D O I
10.3390/jcm10091990
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the late sixties, therapeutic or prophylactic platelet transfusion has been used to relieve hemorrhagic complications of patients with, e.g., thrombocytopenia, platelet dysfunction, and injuries, and is an essential part of the supportive care in high dose chemotherapy. Current and upcoming advances will significantly affect present standards. We focus on specific issues, including the comparison of buffy-coat (BPC) and apheresis platelet concentrates (APC); plasma additive solutions (PAS); further measures for improvement of platelet storage quality; pathogen inactivation; and cold storage of platelets. The objective of this article is to give insights from current practice to future development on platelet transfusion, focusing on these selected issues, which have a potentially major impact on forthcoming guidelines.
引用
收藏
页数:18
相关论文
共 124 条
[1]   Bacterial contamination of platelet components not detected by BacT/ALERT® [J].
Abela, M. A. ;
Fenning, S. ;
Maguire, K. A. ;
Morris, K. G. .
TRANSFUSION MEDICINE, 2018, 28 (01) :65-70
[2]   Frozen platelets and platelet substitutes in transfusion medicine [J].
Alving, BM ;
Reid, TJ ;
Fratantoni, JC ;
Finlayson, JS .
TRANSFUSION, 1997, 37 (08) :866-876
[3]   Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany [J].
an der Heiden, M. ;
Ritter, S. ;
Hamouda, O. ;
Offergeld, R. .
VOX SANGUINIS, 2015, 108 (02) :123-130
[4]   STUDIES OF PLATELET CONCENTRATES STORED AT 22-C AND 4-C [J].
BECKER, GA ;
TUCCELLI, M ;
KUNICKI, T ;
CHALOS, MK ;
ASTER, RH .
TRANSFUSION, 1973, 13 (02) :61-68
[5]  
Benharash P, 2005, AM SURGEON, V71, P776
[6]   Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems [J].
Benjamin, Richard J. ;
Braschler, Thomas ;
Weingand, Tina ;
Corash, Laurence M. .
TRANSFUSION, 2017, 57 (12) :2946-2957
[7]   Intravenous Hemostat: Nanotechnology to Halt Bleeding [J].
Bertram, James P. ;
Williams, Cicely A. ;
Robinson, Rebecca ;
Segal, Steven S. ;
Flynn, Nolan T. ;
Lavik, Erin B. .
SCIENCE TRANSLATIONAL MEDICINE, 2009, 1 (11)
[8]   Bacterial contamination of cellular blood components: risks, sources and control [J].
Blajchman, MA .
VOX SANGUINIS, 2004, 87 :98-103
[9]   Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass [J].
Bode, Arthur P. ;
Lust, Robert M. ;
Read, Marjorie S. ;
Fischer, Thomas H. .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (01) :38-54
[10]   Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview [J].
Bohonek, Milos ;
Kutac, Dominik ;
Acker, Jason P. ;
Seghatchian, Jerard .
TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (02)